337 related articles for article (PubMed ID: 34884607)
1. Genetically Modified Cellular Therapies for Malignant Gliomas.
Kilian M; Bunse T; Wick W; Platten M; Bunse L
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884607
[TBL] [Abstract][Full Text] [Related]
2. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
Front Immunol; 2018; 9():3062. PubMed ID: 30740109
[TBL] [Abstract][Full Text] [Related]
3. Cellular immunotherapy for malignant gliomas.
Lin Y; Okada H
Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
5. IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas.
Killock D
Nat Rev Clin Oncol; 2024 May; 21(5):335. PubMed ID: 38514882
[No Abstract] [Full Text] [Related]
6. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
Morgan RA; Johnson LA; Davis JL; Zheng Z; Woolard KD; Reap EA; Feldman SA; Chinnasamy N; Kuan CT; Song H; Zhang W; Fine HA; Rosenberg SA
Hum Gene Ther; 2012 Oct; 23(10):1043-53. PubMed ID: 22780919
[TBL] [Abstract][Full Text] [Related]
7. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Salinas RD; Durgin JS; O'Rourke DM
CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
[TBL] [Abstract][Full Text] [Related]
8. CAR T cells for brain tumors: Lessons learned and road ahead.
Akhavan D; Alizadeh D; Wang D; Weist MR; Shepphird JK; Brown CE
Immunol Rev; 2019 Jul; 290(1):60-84. PubMed ID: 31355493
[TBL] [Abstract][Full Text] [Related]
9. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
Kwok D; Okada H
J Neurooncol; 2020 Apr; 147(2):281-295. PubMed ID: 32185647
[TBL] [Abstract][Full Text] [Related]
10. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?
Prinzing BL; Gottschalk SM; Krenciute G
Expert Rev Anticancer Ther; 2018 May; 18(5):451-461. PubMed ID: 29533108
[TBL] [Abstract][Full Text] [Related]
11. CD70, a novel target of CAR T-cell therapy for gliomas.
Jin L; Ge H; Long Y; Yang C; Chang YE; Mu L; Sayour EJ; De Leon G; Wang QJ; Yang JC; Kubilis PS; Bao H; Xia S; Lu D; Kong Y; Hu L; Shang Y; Jiang C; Nie J; Li S; Gu Y; Sun J; Mitchell DA; Lin Z; Huang J
Neuro Oncol; 2018 Jan; 20(1):55-65. PubMed ID: 28651374
[TBL] [Abstract][Full Text] [Related]
12. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
[TBL] [Abstract][Full Text] [Related]
13. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
14. Antigen-receptor gene-modified T cells for treatment of glioma.
Ikeda H; Shiku H
Adv Exp Med Biol; 2012; 746():202-15. PubMed ID: 22639170
[TBL] [Abstract][Full Text] [Related]
15. The update of chimeric antigen receptor-T cells therapy in glioblastoma.
Chou CJ; Lin CF; Chen YW; Huang PI; Yang YP; Wang ML; Hung KF; Lee YY
J Chin Med Assoc; 2020 May; 83(5):442-445. PubMed ID: 32217989
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.
Feldman L; Brown C; Badie B
Neurosurgery; 2021 May; 88(6):1056-1064. PubMed ID: 33575786
[TBL] [Abstract][Full Text] [Related]
17. Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.
Riccione K; Suryadevara CM; Snyder D; Cui X; Sampson JH; Sanchez-Perez L
J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741761
[TBL] [Abstract][Full Text] [Related]
18. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
Choi BD; Curry WT; Carter BS; Maus MV
Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]